Sun Pharma shares fall after USFDA halts shipments to the US from Mohali facility

In a setback for Sun Pharma, the company has received a letter from the US Drug Regulator. The letter is titled consent decree correspondence/non compliance letter. The US drug regulator has asked the company to take certain corrective actions at the Mohali facility before releasing final product batches into the US. These actions include retaining an independent Current Good Manufacturing practice expert to conduct batch certifications.